---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-025811"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:49:28.871996+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Medical Technologies starts limited commercial launch of OneRF Ablation System

## Summary
- OneRF System is FDA 510(k)-cleared for creating RF lesions in nervous tissue for functional neurosurgery.
- CEO Dave Rosa expects shipping to begin this week with first cases scheduled in April 2024.
- First therapeutic device for NeuroOne; third FDA 510(k)-cleared device alongside Evo electrode lines.
- Company estimates the brain ablation market at least $100M worldwide with significant growth potential.

## SEC filing metadata
- accession: 0001213900-24-025811
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390024025811/0001213900-24-025811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390024025811/ea0202492-8k_neuro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-025811
- JSON: https://secwatch.observer/filing/0001213900-24-025811.json
- Plain text: https://secwatch.observer/filing/0001213900-24-025811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.